Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 0.0151 | 0.5 | 0.5 |
Trypanosoma brucei | poly(ADP-ribose) glycohydrolase, putative | 0.0151 | 0.5 | 0.5 |
Trypanosoma cruzi | poly(ADP-ribose) glycohydrolase, putative | 0.0151 | 0.5 | 0.5 |
Echinococcus multilocularis | poly(ADP ribose) glycohydrolase | 0.0151 | 0.5 | 0.5 |
Entamoeba histolytica | poly(ADP-ribose) glycohydrolase, putative | 0.0151 | 0.5 | 0.5 |
Toxoplasma gondii | poly(ADP-ribose) glycohydrolase | 0.0151 | 0.5 | 0.5 |
Schistosoma mansoni | poly(ADP-ribose) glycohydrolase | 0.0151 | 0.5 | 0.5 |
Echinococcus granulosus | polyADP ribose glycohydrolase | 0.0151 | 0.5 | 0.5 |
Loa Loa (eye worm) | Poly(ADP-ribose) glycohydrolase | 0.0151 | 0.5 | 0.5 |
Trypanosoma cruzi | poly(ADP-ribose) glycohydrolase, putative | 0.0151 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | uM | Inhibition of binding of [125I]-ET-1 to cloned human Endothelin B receptor expressed in CHO-K1 cells up to 200 microM; non significant | ChEMBL. | No reference |
IC50 (binding) | 0 uM | Inhibition of binding of [125I]-ET-1 to cloned human Endothelin B receptor expressed in CHO-K1 cells up to 200 microM; non significant | ChEMBL. | No reference |
IC50 (functional) | > 25 uM | Antagonistic activity against endothelin A receptor in rabbit renal artery vascular smooth muscle cells. | ChEMBL. | No reference |
IC50 (binding) | > 25 uM | Inhibition of binding of [125I]-ET-1 to cloned human Endothelin A receptor expressed in LtK- cells | ChEMBL. | No reference |
IC50 (functional) | > 25 uM | Antagonistic activity against endothelin A receptor in rabbit renal artery vascular smooth muscle cells. | ChEMBL. | No reference |
IC50 (binding) | > 25 uM | Inhibition of binding of [125I]-ET-1 to cloned human Endothelin A receptor expressed in LtK- cells | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.